Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB127
- Development stage
- Preclinical
- Lead developer
- Virpax Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
NB127 (also known as Naltos Nasal Powder or VRP324) is an intranasal nanoparticle formulation of the small molecule naltrexone, developed for the treatment of Opioid Use Disorder (OUD). The drug utilizes Nanomerics' proprietary Molecular Envelope Technology (MET), which consists of biocompatible polymer nanoparticles designed to encapsulate and deliver drugs directly to the central nervous system via the nose-to-brain pathway. By bypassing the blood-brain barrier and avoiding first-pass hepatic metabolism, NB127 aims to achieve rapid and efficient delivery of naltrexone to the brain. As a mu-opioid receptor antagonist, naltrexone blocks the reinforcing effects of exogenous opioids, thereby reducing cravings and preventing relapse in patients with OUD. The program was developed by Nanomerics and has been out-licensed to Virpax Pharmaceuticals for clinical development.
- Brand names
- NaltosEnvelta
- Other names
- Naltos Nasal PowderEnvelta Nasal Powder
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on NB127.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB127.